Feb. 3, 2020 – How much effect the status of drug product endorsers – be they celebrities, physicians, patients or social media influencers – has on consumers is the subject of a new study proposed by the FDA’s Office of Prescription Drug Promotion (OPDP) in the Jan. 28 Federal Register. “We are interested in the […]
Read moreOct. 6, 2104 – Although the FDA’s Office of Prescription Drug Promotion (OPDP) recently reopened the comment period for its two social media draft guidances, all three major industry trade associations – the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO) and the Advanced Medical Technology Association (AdvaMed) – already had […]
Read moreSept. 30, 2014 – Companies striving to use social media marketing both effectively and appropriately likely will benefit from a new Master Class, “Using Social Media Compliantly.” The one-day class, to be held Nov. 12 in Princeton, N.J., and Nov. 18 in Boston, is being offered by PhillyCooke Consulting and will enable attendees “to take […]
Read moreJuly 21, 2014 – Although the FDA has attempted to provide some clarity on its position regarding certain social media issues and practices, the agency’s recent draft guidance documents do not leave industry communicators with a crystal clear path and, indeed, “raise some important questions that communicators may have for their counsel,” according to Mark […]
Read moreJune 23, 2014 – Although the two social media draft guidance documents the FDA’s Office of Prescription Drug Promotion (OPDP) issued June 17 do not exactly establish any new marketing policy, they do help industry to understand what is expected by the agency in several online forums, according to Coalition for Healthcare Communication Executive Director […]
Read moreApril 9, 2014 — The Coalition for Healthcare Communication issued the following press release today regarding the CHC Social Media Comment it submitted yesterday on the FDA draft guidance issued in January. FOR IMMEDIATE RELEASE: CONTACT: John Kamp Executive Director Coalition for Healthcare Communication 703-801-4582 (mobile) jkamp@cohealthcom.org CHC Comment on Social Media Draft Guidance Calls […]
Read moreJan. 14, 2014 – The determining factor regarding whether a firm submits online prescription drug promotional material to the agency is “whether the firm or anyone acting on its behalf is influencing or controlling the product promotional activity or communication in whole or part,” according to a recent FDA Draft Guidance, “Fulfilling Regulatory Requirements for […]
Read moreSept. 9, 2013 – In a recent blog post on Drugwonks.com, entitled “Tweeter Reflux,” Peter Pitts reminded industry that although social media may pose complex questions, sponsored tweets are not that complicated. They are paid advertisements, pure and simple. Pitts cites AstraZeneca’s recent withdrawal of paid ads from the Associated Press’ Twitter feed because although […]
Read moreApril 4, 2013 – A new White Paper, “,” issued April 2 by Eye on FDA/Fleishman-Hillard, is based on analysis of a database of FDA/Office of Prescription Drug Promotion (OPDP) enforcement letters, and takes a close look at how, in the absence of FDA guidance on digital communications and social media, the agency enforces alleged violations […]
Read moreMarch 19, 2013 – Although the FDA has not yet issued its long-awaited social media guidance for the biopharma industry, whatever guidelines it drafts on this topic are likely to be informed by the staff guidance document issued last week by the Federal Trade Commission (FTC). The FTC’s new guidance, “.com Disclosures,” revises an FTC […]
Read more